miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 9, 2026

Aduro Clean Technologies Unveils Low-Energy Recycling Tech, Eyes First Netherlands Unit Scaling Up

View original at finance.yahoo.com
“Aduro says it is funded with about CAD 40 million and remains focused on execution.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The pilot system is commissioned and the team is troubleshooting, doing a lot of learning out of it

    60% confidence
  • Aduro's addressable market across its segments is more than $200 billion today

    60% confidence
  • Modular commercial units can be built in under a year

    60% confidence
  • Aduro's process produces circular naphtha—an oil-like output—from waste plastic

    60% confidence
  • HCT operates at lower energy, offers higher tolerance to contamination, and delivers a higher yield of materials that can return to plastic building blocks compared to pyrolysis

    60% confidence
  • Permitting and regulation are the main near-term hurdle to meeting a 2027 revenue/commissioning target

    60% confidence
  • Today, in 2026, we have an up and running pilot

    60% confidence
  • The company is quite aggressive in its approach

    60% confidence
  • Aduro is funded with about CAD 40 million

    60% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · addressable market200 USD
Aduro Clean Technologies Inc. · cash40 million_CAD
Aduro Clean Technologies Inc. · module capacity25000 tons_per_module
Aduro Clean Technologies Inc. · target capacity100000 tons
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com